Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.

Dirk Jan A R MoesDavid J van WesterlooSandra M ArendJesse J SwenAnnick de VriesHenk-Jan GuchelaarSimone A JoostenMark G J de BoerTeun van GelderJudith van Paassen

Published in: Clinical pharmacokinetics (2021)

This study provides evidence to support a fixed dose of tocilizumab 600 mg in COVID-19 patients. Fixed dosing is a safe, logistically attractive, and drug expenses saving alternative compared with the current 8 mg/kg recommendation.

Keyphrases

rheumatoid arthritis
sars cov
intensive care unit
cross sectional
emergency department
rheumatoid arthritis patients